Table 1.
Comparison of general data
| Observation index | Observation (n=31) | Control (n=30) | P |
|---|---|---|---|
| Male | 24 (77.7) | 21 (70) | 0.513 |
| Age (years) | 61.7±11.2 | 68.6±9.4 | 0.103 |
| Body weight (kg) | 68.8±6.6 | 70.5±6.4 | 0.295 |
| Smoking history | 23 (74.4) | 24 (80.0) | 0.592 |
| Diabetes | 8 (25.6) | 7 (23.5) | 0.825 |
| Hypertension | 13 (41.7) | 15 (50.0) | 0.525 |
| Cerebral apoplexy | 7 (22.4) | 9 (30.0) | 0.513 |
| Hyperlipidemia | 11 (35.3) | 16 (53.5) | 0.163 |
| Killip III number | 13 (41.7) | 15 (50.0) | 0.525 |
| NSTEMI number | 8 (25.6) | 11 (36.6) | 0.363 |
| Postoperative TIMI blood flow grade 3 | 31 (100) | 30 (100) | 1.000 |
| DAPT | 31 (100) | 30 (100) | 1.000 |
| Pitavastatin Calcium Tablets | 31 (100) | 30 (100) | 1.000 |
| Metoprolol tartrate tablets | 31 (100) | 30 (100) | 1.000 |
| Spironolactone tablets | 31 (100) | 30 (100) | 1.000 |
| Furosemide tablets | 31 (100) | 30 (100) | 1.000 |
| TG (mmol/L) | 1.8±1.3 | 1.7±1.8 | 0.726 |
| CHOL (mmol/L) | 5.2±1.6 | 4.6±1.2 | 0.097 |
| HDL-C (mmol/L) | 1.5±0.5 | 1.4±0.5 | 0.064 |
| LDL-C (mmol/L) | 3.3±1.3 | 2.6±0.6 | 0.082 |
| FPG (mmol/L) | 5.5±1.5 | 5.5±1.3 | 0.155 |
Note: NSTEMI: Non-ST-segment Elevation Myocardial Infarction, DAPT: Dual Antiplatelet Therapy, TIMI: Thrombolysis in Myocardial Infarction, TG: Triglycerides, CHOL: Cholesterol, HDL-C: High-Density Lipoprotein Cholesterol, LDL-C: Low-Density Lipoprotein Cholesterol, FPG: Fasting Plasma Glucose.